A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Phase of Trial: Phase I/II
Latest Information Update: 01 Apr 2019
Price : $35 *
At a glance
- Drugs Imatinib (Primary) ; Infigratinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- 26 Mar 2019 Status changed from active, no longer recruiting to completed.
- 26 Oct 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 26 Oct 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.